Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:10801894rdf:typepubmed:Citationlld:pubmed
pubmed-article:10801894lifeskim:mentionsumls-concept:C0034802lld:lifeskim
pubmed-article:10801894lifeskim:mentionsumls-concept:C1706586lld:lifeskim
pubmed-article:10801894lifeskim:mentionsumls-concept:C0752312lld:lifeskim
pubmed-article:10801894lifeskim:mentionsumls-concept:C1370600lld:lifeskim
pubmed-article:10801894lifeskim:mentionsumls-concept:C0752313lld:lifeskim
pubmed-article:10801894lifeskim:mentionsumls-concept:C0812215lld:lifeskim
pubmed-article:10801894lifeskim:mentionsumls-concept:C2746015lld:lifeskim
pubmed-article:10801894lifeskim:mentionsumls-concept:C1515877lld:lifeskim
pubmed-article:10801894lifeskim:mentionsumls-concept:C1879547lld:lifeskim
pubmed-article:10801894lifeskim:mentionsumls-concept:C1521840lld:lifeskim
pubmed-article:10801894lifeskim:mentionsumls-concept:C0136157lld:lifeskim
pubmed-article:10801894pubmed:issue29lld:pubmed
pubmed-article:10801894pubmed:dateCreated2000-8-24lld:pubmed
pubmed-article:10801894pubmed:abstractTextActivation of ERK-1 and -2 by H(2)O(2) in a variety of cell types requires epidermal growth factor receptor (EGFR) phosphorylation. In this study, we investigated the activation of ERK by ONOO(-) in cultured rat lung myofibroblasts. Western blot analysis using anti-phospho-ERK antibodies along with an ERK kinase assay using the phosphorylated heat- and acid-stable protein (PHAS-1) substrate demonstrated that ERK activation peaked within 15 min after ONOO(-) treatment and was maximally activated with 100 micrometer ONOO(-). Activation of ERK by ONOO(-) and H(2)O(2) was blocked by the antioxidant N-acetyl-l-cysteine. Catalase blocked ERK activation by H(2)O(2), but not by ONOO(-), demonstrating that the effect of ONOO(-) was not due to the generation of H(2)O(2). Both H(2)O(2) and ONOO(-) induced phosphorylation of EGFR in Western blot experiments using an anti-phospho-EGFR antibody. However, the EGFR tyrosine kinase inhibitor AG1478 abolished ERK activation by H(2)O(2), but not by ONOO(-). Both H(2)O(2) and ONOO(-) activated Raf-1. However, the Raf inhibitor forskolin blocked ERK activation by H(2)O(2), but not by ONOO(-). The MEK inhibitor PD98059 inhibited ERK activation by both H(2)O(2) and ONOO(-). Moreover, ONOO(-) or H(2)O(2) caused a cytotoxic response of myofibroblasts that was prevented by preincubation with PD98059. In a cell-free kinase assay, ONOO(-) (but not H(2)O(2)) induced autophosphorylation and nitration of a glutathione S-transferase-MEK-1 fusion protein. Collectively, these data indicate that ONOO(-) activates EGFR and Raf-1, but these signaling intermediates are not required for ONOO(-)-induced ERK activation. However, MEK-1 activation is required for ONOO(-)-induced ERK activation in myofibroblasts. In contrast, H(2)O(2)-induced ERK activation is dependent on EGFR activation, which then leads to downstream Raf-1 and MEK-1 activation.lld:pubmed
pubmed-article:10801894pubmed:granthttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10801894pubmed:languageenglld:pubmed
pubmed-article:10801894pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10801894pubmed:citationSubsetIMlld:pubmed
pubmed-article:10801894pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10801894pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10801894pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10801894pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10801894pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10801894pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10801894pubmed:statusMEDLINElld:pubmed
pubmed-article:10801894pubmed:monthJullld:pubmed
pubmed-article:10801894pubmed:issn0021-9258lld:pubmed
pubmed-article:10801894pubmed:authorpubmed-author:KaganEElld:pubmed
pubmed-article:10801894pubmed:authorpubmed-author:WangY ZYZlld:pubmed
pubmed-article:10801894pubmed:authorpubmed-author:ZhangPPlld:pubmed
pubmed-article:10801894pubmed:authorpubmed-author:BonnetJ AJAlld:pubmed
pubmed-article:10801894pubmed:issnTypePrintlld:pubmed
pubmed-article:10801894pubmed:day21lld:pubmed
pubmed-article:10801894pubmed:volume275lld:pubmed
pubmed-article:10801894pubmed:ownerNLMlld:pubmed
pubmed-article:10801894pubmed:authorsCompleteYlld:pubmed
pubmed-article:10801894pubmed:pagination22479-86lld:pubmed
pubmed-article:10801894pubmed:dateRevised2009-11-19lld:pubmed
pubmed-article:10801894pubmed:meshHeadingpubmed-meshheading:10801894...lld:pubmed
pubmed-article:10801894pubmed:meshHeadingpubmed-meshheading:10801894...lld:pubmed
pubmed-article:10801894pubmed:meshHeadingpubmed-meshheading:10801894...lld:pubmed
pubmed-article:10801894pubmed:meshHeadingpubmed-meshheading:10801894...lld:pubmed
pubmed-article:10801894pubmed:meshHeadingpubmed-meshheading:10801894...lld:pubmed
pubmed-article:10801894pubmed:meshHeadingpubmed-meshheading:10801894...lld:pubmed
pubmed-article:10801894pubmed:meshHeadingpubmed-meshheading:10801894...lld:pubmed
pubmed-article:10801894pubmed:meshHeadingpubmed-meshheading:10801894...lld:pubmed
pubmed-article:10801894pubmed:meshHeadingpubmed-meshheading:10801894...lld:pubmed
pubmed-article:10801894pubmed:meshHeadingpubmed-meshheading:10801894...lld:pubmed
pubmed-article:10801894pubmed:year2000lld:pubmed
pubmed-article:10801894pubmed:articleTitlePeroxynitrite targets the epidermal growth factor receptor, Raf-1, and MEK independently to activate MAPK.lld:pubmed
pubmed-article:10801894pubmed:affiliationLaboratory of Pulmonary Pathobiology, NIEHS, National Institutes of Health, Research Triangle Park, North Carolina 27709, USA.lld:pubmed
pubmed-article:10801894pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:10801894pubmed:publicationTypeResearch Support, U.S. Gov't, P.H.S.lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:10801894lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:10801894lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:10801894lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:10801894lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:10801894lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:10801894lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:10801894lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:10801894lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:10801894lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:10801894lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:10801894lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:10801894lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:10801894lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:10801894lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:10801894lld:pubmed